SCIENTURE HOLDINGS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
SCIENTURE HOLDINGS, INC. (SCNX) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$41.51 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-03-30
- SCIENTURE HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$28.12M.
- SCIENTURE HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$3.61M.
- SCIENTURE HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$6.72M.
- SCIENTURE HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$3.06M.
- SCIENTURE HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$41.51M.
- SCIENTURE HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$18.24M.
- SCIENTURE HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$8.48M.
- SCIENTURE HOLDINGS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2017 was $288.98K.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$28.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$31.73M derived: sum of 2 quarters · filed 2026-03-30 | -$38.45M derived: sum of 3 quarters · filed 2026-03-30 | -$41.51M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$3.61M 10-Q · filed 2025-11-12 | -$10.33M derived: sum of 2 quarters · filed 2025-11-12 | -$13.39M 10-Q · filed 2025-11-12 | -$20.19M derived: sum of 4 quarters · filed 2026-03-30 |
| 2025-06-30 | -$6.72M 10-Q · filed 2025-08-12 | -$9.78M 10-Q · filed 2025-08-12 | -$16.59M derived: sum of 3 quarters · filed 2026-03-30 | -$19.77M derived: sum of 4 quarters · filed 2026-03-30 |
| 2025-03-31 | -$3.06M 10-Q · filed 2025-05-12 | -$9.87M derived: sum of 2 quarters · filed 2026-03-30 | -$13.05M derived: sum of 3 quarters · filed 2026-03-30 | -$14.68M derived: sum of 4 quarters · filed 2026-03-30 |
| 2024-12-31 | -$6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$9.99M derived: sum of 2 quarters · filed 2026-03-30 | -$11.61M derived: sum of 3 quarters · filed 2026-03-30 | -$18.24M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$3.18M 10-Q · filed 2025-11-12 | -$4.81M derived: sum of 2 quarters · filed 2025-11-12 | -$11.44M 10-Q · filed 2025-11-12 | -$16.50M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.62M 10-Q · filed 2025-08-12 | -$8.26M 10-Q · filed 2025-08-12 | -$13.31M derived: sum of 3 quarters · filed 2025-08-12 | -$13.40M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$6.63M 10-Q · filed 2025-05-12 | -$11.69M derived: sum of 2 quarters · filed 2025-05-12 | -$11.78M derived: sum of 3 quarters · filed 2025-05-12 | -$14.00M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$5.14M derived: sum of 2 quarters · filed 2025-03-26 | -$7.37M derived: sum of 3 quarters · filed 2025-03-26 | -$8.48M 10-K · filed 2025-03-26 |
| 2023-09-30 | -$88.14K 10-Q · filed 2024-11-06 | -$2.32M derived: sum of 2 quarters · filed 2024-11-06 | -$3.43M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$2.23M 10-Q · filed 2024-08-09 | -$3.34M 10-Q · filed 2024-08-09 | ||
| 2018-09-30 | $94.25K 10-Q · filed 2018-10-26 | $114.76K derived: sum of 2 quarters · filed 2018-10-26 | $197.03K 10-Q · filed 2018-10-26 | $336.94K derived: sum of 4 quarters · filed 2018-10-26 |
| 2018-06-30 | $20.51K 10-Q · filed 2018-07-27 | $102.78K 10-Q · filed 2018-07-27 | $242.69K derived: sum of 3 quarters · filed 2018-07-27 | $318.88K derived: sum of 4 quarters · filed 2018-07-27 |
| 2018-03-31 | $82.27K 10-Q · filed 2018-04-27 | $222.18K derived: sum of 2 quarters · filed 2018-04-27 | $298.37K derived: sum of 3 quarters · filed 2018-04-27 | $291.53K derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-12-31 | $139.91K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | $216.10K derived: sum of 2 quarters · filed 2018-03-02 | $209.26K derived: sum of 3 quarters · filed 2018-03-02 | $288.98K 10-K · filed 2018-03-02 |
| 2017-09-30 | $76.19K 10-Q · filed 2017-11-07 | $69.35K derived: sum of 2 quarters · filed 2017-11-07 | $149.08K 10-Q · filed 2017-11-07 | $87.60K derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-06-30 | -$6.84K 10-Q · filed 2017-08-04 | $72.88K 10-Q · filed 2017-08-04 | $11.41K derived: sum of 3 quarters · filed 2018-04-27 | -$284.07K derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-03-31 | $79.73K 10-Q · filed 2018-04-27 | $18.25K derived: sum of 2 quarters · filed 2018-04-27 | -$277.23K derived: sum of 3 quarters · filed 2018-04-27 | -$922.18K derived: sum of 4 quarters · filed 2018-04-27 |
| 2016-12-31 | -$61.48K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | -$356.95K derived: sum of 2 quarters · filed 2018-03-02 | -$1.00M derived: sum of 3 quarters · filed 2018-03-02 | -$1.17M 10-K · filed 2018-03-02 |
| 2016-09-30 | -$295.48K 10-Q · filed 2017-11-07 | -$940.43K derived: sum of 2 quarters · filed 2017-11-07 | -$1.11M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | -$644.95K 10-Q · filed 2017-08-04 | -$816.16K 10-Q · filed 2017-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |